Center for the Study of Drugs, Alcohol, Smoking and Health, School of Nursing, University of Michigan, Ann Arbor.
Institute for Research on Women and Gender, University of Michigan, Ann Arbor.
JAMA Netw Open. 2023 Apr 3;6(4):e238707. doi: 10.1001/jamanetworkopen.2023.8707.
Recent information on the prevalence of prescription stimulant therapy for attention-deficit/hyperactivity disorder (ADHD) and nonmedical use of prescription stimulants (NUPS) at the school-level among US secondary school students is limited.
To investigate the school-level prevalence of and association between stimulant therapy for ADHD and NUPS among US secondary school students.
DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used survey data collected between 2005 and 2020 as part of the Monitoring the Future study (data collected annually via self-administered survey in schools from independent cohorts). Participants were from a nationally representative sample of 3284 US secondary schools. The mean (SD) response rates were 89.5% (1.3%) for 8th-grade students, 87.4% (1.1%) for 10th-grade students, and 81.5% (1.8%) for 12th-grade students. Statistical analysis was performed from July to September 2022.
Past-year NUPS.
The 3284 schools contained 231 141 US 8th-, 10th-, and 12th-grade students (111 864 [50.8%, weighted] female; 27 234 [11.8%, weighted] Black, 37 400 [16.2%, weighted] Hispanic, 122 661 [53.1%, weighted] White, 43 846 [19.0%, weighted] other race and ethnicity). Across US secondary schools, the past-year prevalence of NUPS ranged from 0% to more than 25%. The adjusted odds of an individual engaging in past-year NUPS were higher at secondary schools with higher proportions of students who reported stimulant therapy for ADHD, after controlling for other individual-level and school-level covariates. Students attending schools with the highest rates of prescription stimulant therapy for ADHD had approximately 36% increased odds of past-year NUPS compared with students attending schools with no medical use of prescription stimulants (adjusted odds ratio, 1.36; 95% CI, 1.20-1.55). Other significant school-level risk factors included schools in more recent cohorts (2015-2020), schools with higher proportions of parents with higher levels of education, schools located in non-Northeastern regions, schools located in suburban areas, schools with higher proportion of White students, and schools with medium levels of binge drinking.
In this cross-sectional study of US secondary schools, the prevalence of past-year NUPS varied widely, highlighting the need for schools to assess their own students rather than relying solely on regional, state, or national results. The study offered new evidence of an association between a greater proportion of the student body that uses stimulant therapy and a greater risk for NUPS in schools. The association between greater school-level stimulant therapy for ADHD and other school-level risk factors suggests valuable targets for monitoring, risk-reduction strategies, and preventive efforts to reduce NUPS.
最近有关美国中学学生 ADHD 处方兴奋剂治疗和非医疗用途处方兴奋剂(NUPS)的流行率的信息有限,仅限于学校层面。
调查美国中学学生 ADHD 处方兴奋剂治疗和 NUPS 之间的学校层面流行率和关联。
设计、设置和参与者:这项横断面研究使用了 2005 年至 2020 年期间作为监测未来研究(通过学校从独立队列中每年进行自我管理调查收集的数据)一部分收集的调查数据。参与者来自美国全国代表性的 3284 所中学的样本。8 年级学生的平均(SD)应答率为 89.5%(1.3%),10 年级学生为 87.4%(1.1%),12 年级学生为 81.5%(1.8%)。统计分析于 2022 年 7 月至 9 月进行。
过去一年的 NUPS。
3284 所学校包含 231411 名美国 8 年级、10 年级和 12 年级学生(111864 名[50.8%,加权]女性;27234 名[11.8%,加权]黑人,37400 名[16.2%,加权]西班牙裔,122661 名[53.1%,加权]白人,43846 名[19.0%,加权]其他种族和民族)。在美国中学,过去一年 NUPS 的流行率从 0%到 25%以上不等。在控制了其他个体和学校层面的协变量后,报告 ADHD 患者接受兴奋剂治疗的比例较高的学校中,个体过去一年使用 NUPS 的可能性更高。与没有接受处方兴奋剂治疗的学生相比,接受 ADHD 最高处方兴奋剂治疗的学校的学生过去一年使用 NUPS 的几率增加了约 36%(调整后的比值比,1.36;95%CI,1.20-1.55)。其他显著的学校层面风险因素包括属于较新队列(2015-2020 年)的学校、父母受教育程度较高的比例较高的学校、位于非东北部地区的学校、位于郊区的学校、白人学生比例较高的学校以及中等程度 binge 饮酒的学校。
在这项对美国中学的横断面研究中,过去一年 NUPS 的流行率差异很大,这突出表明学校需要评估自己的学生,而不仅仅是依赖于地区、州或全国的结果。该研究提供了新的证据,证明了学生群体中使用兴奋剂治疗的比例与学校中 NUPS 风险增加之间存在关联。ADHD 学生接受更大比例的学校兴奋剂治疗与其他学校层面的风险因素之间的关联表明,监测、减少风险策略和预防措施具有重要的目标,可以减少 NUPS。